ACRSAclaris Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Aclaris Therapeutics, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACRSEsta | $567M#4 | — | 4.5x#4 | 72.4x#2 | -58.2%#2 | 50.8%#3 | -975.9%#2 | -52.1%#4 | -65.8%#3 | 3#1 | 52.8%#1 | — |
| LXRX | $627M#1 | — | 3.6x#3 | 12.6x#1 | 60.2%#1 | 74.9%#1 | -98.2%#1 | -28.8%#1 | -26.4%#2 | — | — | — |
| NVCT | $596M#2 | — | 65.6x#5 | — | — | -39.2%#5 | — | -291.1%#6 | — | — | — | — |
| ANNX | — | — | — | — | — | -49.6%#6 | — | -111.1%#5 | — | — | 24.5%#2 | — |
| GERN | $578M#3 | — | 2.6x#2 | 2440.0x#3 | -60.2%#3 | 52.2%#2 | -28938.8%#3 | -38.2%#2 | -24.8%#1 | — | -28.6%#3 | — |
| NGNE | $538M#5 | — | 2.5x#1 | — | -100.0%#4 | -20.2%#4 | — | -41.6%#3 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-11-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice